Sarepta Therapeutics, Inc.: STATE STREET CORP discloses a stake of more than 5% (Schedule 13G)
Open the sourceReported by SEC EDGAR SCHEDULE 13G, sec.gov, 10 November 2026, by SEC EDGAR SCHEDULE 13G
30
Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.
State Street Corp. disclosed a stake exceeding 5% in Sarepta Therapeutics in a Schedule 13G filing with the SEC (accession 0000093751-26-000721). The passive-investor threshold crossing makes State Street a notable holder in the gene-therapy developer. The exact share count and percentage were not specified in the filing headline. Investors will watch for further 13G amendments for precise ownership figures and any shifts in institutional positioning.
Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.
Named in this story
Sarepta Therapeutics, Inc., State Street Corp